Latest News for: symptomatic
Edit
Novartis Rhapsido® (remibrutinib) receives FDA approval as first treatment for symptomatic dermographism (SD), expanding its ...
Nasdaq Globe Newswire 07 Oct 2026
... for adults with symptomatic dermographism (SD) inadequately controlled by H1 antihistamines.
Edit
DKSH Singapore Business Unit Healthcare Introduces a New Treatment Option for Adult Symptomatic Chronic Heart Failure (DKSH Holding AG)
Public Technologies 05 Oct 2026
Oct 05, 2026 DKSH Singapore Business Unit Healthcare Introduces a New Treatment Option for Adult Symptomatic Chronic Heart Failure ... In patients with symptomatic chronic heart failure and LVEF ≥40%, ...
Edit
Cytokinetics Launches ASPEN-HCM: A Real-World Study Evaluating MYQORZO� (aficamten) in Symptomatic Obstructive Hypertrophic Cardiomyopathy
Nasdaq Globe Newswire 30 Sep 2026
Edit
Scientists Discover Key Biological Link Between Endometriosis and Chronic Pain
Mega Doctor News 22 Sep 2026
To learn more about how endometriosis causes pain at the molecular level, Yale School of Medicine researchers studied biopsies from patients with either symptomatic or asymptomatic endometriosis.
Edit
ENA Respiratory Begins Part B Dosing in INNA-051 Phase IIa Community Study Designed to Protect Against Symptomatic Viral Respiratory Infections (Brandon Capital Partners Pty Ltd)
Public Technologies 16 Sep 2026
[...]. This is an abstract of the document. To keep reading, click here and get access to the original version. Attachments Original document Permalink. Disclaimer ... (noodl.
Edit
Pulse Biosciences Completes Enrollment in the PRECISE-BTN Clinical Study Evaluating the nPulse™ Vybrance™ Percutaneous Electrode System for Symptomatic Benign Thyroid Nodules (Form 8-K) (Pulse Biosciences Inc)
Public Technologies 15 Sep 2026
Pulse Biosciences Completes Enrollment in the PRECISE-BTN Clinical Study Evaluating the nPulse™ Vybrance™ Percutaneous Electrode System for Symptomatic Benign Thyroid Nodules.
Edit
Organogenesis Announces FDA Acceptance of Biologics License Application for ReNu® for the Management of Symptomatic Knee Osteoarthritis (Organogenesis Holdings Inc)
Public Technologies 06 Jul 2026
... for the treatment of pain in symptomatic knee osteoarthritis (OA) ... ReNu® is a cryopreserved, amniotic suspension allograft developed for the treatment of pain in symptomatic knee osteoarthritis.
- 1